Economic evaluation of drug-eluting stents: A systematic literature review and model-based cost-utility analysis

International Journal of Technology Assessment in Health Care

Volumn 23, Issue 4, 2007, Pages 473-479

  Kuukasjärvi, Pekka ^a   Räsänen, Pirjo ^a   Malmivaara, Antti ^a   Aronen, Pasi ^a   Sintonen, Harri ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Coronary artery disease; Cost effectiveness; Cost utility; Health related quality of life; Quality adjusted life year; Stent; Systematic review of literature

Indexed keywords

BARE METAL STENTS (BMS); CORONARY ARTERY DISEASES; ECONOMIC EVALUATION; HEALTH RELATED QUALITY OF LIFE; SYSTEMATIC REVIEWS;

COST EFFECTIVENESS; DATABASE SYSTEMS; DISEASES; ECONOMIC ANALYSIS; PATIENT TREATMENT;

DRUG PRODUCTS;

ARTICLE; COCHRANE LIBRARY; CORONARY ARTERY DISEASE; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DATA BASE; DRUG ELUTING STENT; ECONOMIC EVALUATION; HUMAN; MEDLINE; QUALITY OF LIFE; REVASCULARIZATION; SYSTEMATIC REVIEW;

CORONARY ARTERY DISEASE; COST-BENEFIT ANALYSIS; DRUG-ELUTING STENTS; FINLAND; HUMANS; MODELS, ECONOMIC; QUALITY-ADJUSTED LIFE YEARS; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 35348838324     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S0266462307070560     Document Type: Article

References (16)

1. Bagust A, Grayson AD, Palmer ND, et al. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: Cost-utility study. Heart. 2006;92:68-74.
2. Bowen J, Hopkins R, He Y, et al. Systematic review and cost-effectiveness analysis of drug eluting stents compared to bare metal stents for percutaneous coronary interventions in Ontario. Interim Report for the Ontario Ministry of Health and Long-term Care. Program for Assessment of Technology in Health. Report No.: HTA002-0512. Ontario: McMaster University; 2005:170.
3. Brophy JM, Erickson LJ. Cost-effectiveness of drug-eluting coronary stents in Quebec, Canada. Int J Technol Assess Health Care. 2005;21:326-333.
4. Cohen DJ, Bakhai A, Shi C, et al. Cost-effectiveness of sirolimus-eluting stents for treatment of complex coronary stenoses: Results from the sirolimus-eluting balloon expandable stent in the treatment of patients with de novo native coronary artery lesions (SIRIUS) trial. Circulation. 2004;110:508-514.
5. Drummond M, Sculpher M, Torrance GW. Methods for the economic evaluation of health care programmes. Oxford: Oxford University Press; 2005.
6. Hill R, Bagust A, Bakhai A, et al. Coronary artery stents: A rapid systematic review and economic evaluation. Health Technol Assess. 2004;8:iii-iv, 1-242.
7. Kaiser C, Brunner-La Rocca HP, Buser PT, et al. Incremental cost-effectiveness of drug-eluting stents compared with a third-generation bare-metal stent in a real-world setting: Randomised Basel Stent Kosten Effektivitats Trial (BASKET). Lancet. 2005;366:921-929.
8. Kattainen E, Sintonen H, Kettunen R, Merilainen P. Health-related quality of life of coronary artery bypass grafting and percutaneous transluminal coronary artery angioplasty patients: 1-year follow-up. Int J Technol Assess Health Care. 2005;21:172-179.
9. Kong DF, Eisenstein EL, Sketch MH Jr, et al. Economic impact of drug-eluting stents on hospital systems: A disease-state model. Am Heart J. 2004;147:449-456.
10. Medical Services Advisory C. Drug-eluting stents. Canberra: Medical Services Advisory Committee (MSAC); 2005.
11. Mittmann N, Brown A, Seung SJ, et al. Economic evaluation of drug eluting stents. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA); 2005.
12. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354:1896-1900.
13. Oliva G, Espallargues M, Pons JM. [Antiproliferative drug-eluting stents: Systematic review of the benefits and estimate of economic impact]. Rev Esp Cardiol. 2004;57:617-628.
14. Shrive FM, Manns BJ, Galbraith PD, et al. Economic evaluation of sirolimus-eluting stents. CMAJ. 2005;172:345-351.
15. The Norwegian Knowledge Centre for the Health Services (NOKC); 2004. Prevention of restenosis (8/2004). Available at: http://www. kunnskapssenteret.no/filer/Rapport8-2004_siste_versjon.pdf.
16. van Hout BA, Serruys PW, Lemos PA, et al. One year cost effectiveness of sirolimus eluting stents compared with bare metal stents in the treatment of single native de novo coronary lesions: An analysis from the RAVEL trial. Heart. 2005;91:507-512.